Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution
2010

Non-Hodgkin Lymphoma After Starting New HIV Treatments

Sample size: 78 publication Evidence: moderate

Author Information

Author(s): Gregory D Huhn, Sheila Badri, Sonia Vibhakar, Frank Tverdek, Christopher Crank, Ronald Lubelchek, Blake Max, David Simon, Beverly Sha, Oluwatoyin Adeyemi, Patricia Herrera, Allan Tenorio, Harold Kessler, David Barker

Primary Institution: The Ruth M. Rothstein CORE Center

Hypothesis

What immunologic and virologic factors are associated with the rapid development of non-Hodgkin lymphoma (NHL) in HIV-infected patients after starting newer-class antiretroviral therapy?

Conclusion

The study found a surprisingly high rate of NHL among HIV patients who had a good virologic response to newer antiretrovirals, suggesting that immune reconstitution may play a role in NHL development.

Supporting Evidence

  • Five cases of NHL were identified among 78 patients, indicating a mean incidence of 64.1 per 1000 patient-years.
  • The median time from starting new antiretrovirals to NHL symptom onset was 5 weeks.
  • At week 12, NHL cases showed a mean viral load reduction of 2.79 compared to 1.94 in controls.

Takeaway

Some HIV patients developed a type of cancer called non-Hodgkin lymphoma shortly after starting new medications, even though these medications usually help them get better.

Methodology

The study analyzed cases of NHL among HIV-infected patients who started newer-class antiretrovirals, comparing their immunologic and virologic data to controls without NHL.

Potential Biases

The study may have missed NHL cases that were present before starting treatment, and the small sample size could introduce bias.

Limitations

The observational nature of the study may not account for all risk factors for NHL, and the small sample size limits the precision of the analysis.

Participant Demographics

Median age of participants was 46 years, with 80% of NHL cases being male.

Statistical Information

P-Value

0.045

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1742-6405-7-44

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication